Press release Biocartis Group

BIOCARTIS ANNOUNCES RESIGNATION CFO

PRESS RELEASE:  REGULATED INFORMATION – INSIDE INFORMATION   

27 January 2020, 07:00 CET

BIOCARTIS ANNOUNCES RESIGNATION CFO

Mechelen, Belgium, 27 January 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that Ewoud Welten, the Company’s Chief Financial Officer (‘CFO’), has decided to resign from Biocartis and to pursue an opportunity in the Netherlands, closer to his home and family.

Biocartis has initiated a selection process to recruit a new CFO. The Company and Mr. Welten have agreed that he will stay with Biocartis until the end of March 2020 to ensure a smooth transition for the Company.

Herman Verrelst, Chief Executive Officer of Biocartis, commented: “Ewoud has been with us for around 5 years and during this time he has been a valuable asset to the company. He was instrumental in securing the necessary financing for the Company and leaves behind strong teams in finance, legal and investor relations ready to support the Company’s ambitious growth plans for the next years. I am sorry to see him go but respect his decision. We wish him all the best.”

--- END ---

More information:

Renate Degrave
Head of Corporate Communications & Investor Relations Biocartis
e-mail   [e-mail]
tel         [phone]
mobile   [phone]

About Biocartis 

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs in oncology. This represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.